Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma

T cell checkpoint blockade with antibodies targeting programmed cell death (ligand)-1 (PD-1/PD-L1) and/or cytotoxic T lymphocyte-antigen 4 (CTLA-4) has improved therapy outcome in melanoma patients. However, a considerable proportion of patients does not benefit even from combined α-CTLA-4 and α-PD-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroon, Paula, Gadiot, Jules, Peeters, Marlies, Gasparini, Alessia, Deken, Marcel A., Yagita, Hideo, Verheij, Marcel, Borst, Jannie, Blank, Christian U., Verbrugge, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880641/
https://www.ncbi.nlm.nih.gov/pubmed/27160390
http://dx.doi.org/10.1007/s00262-016-1843-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880641/
https://www.ncbi.nlm.nih.gov/pubmed/27160390
http://dx.doi.org/10.1007/s00262-016-1843-4

Ejemplares similares